Evaluation of risperidone in the neonatal 6-hydroxydopamine model of Lesch-Nyhan syndrome.
Rats were treated as neonates with 6-hydroxydopamine (6-OHDA) 100 mg free base in 10 microl intracisternally. Upon maturation, animals were injected with L-dopa and placed in photocell cages for monitoring of locomotion, stereotypies, and self-mutilation. Pretreatment with either risperidone or SCH-23390 significantly reduced locomotion and stereotypies. SCH-23390 eliminated L-dopa induced self-mutilation in all subjects, while risperidone eliminated self-mutilation in all but one subject.
Allen
S M
SM
Department of Pharmacology and the Research Institute of Pharmacological Sciences, University of Mississippi, University 38677, USA.
Freeman
J N
JN
Davis
W M
WM
D000818:Animals; D000831:Animals, Newborn; D001522:Behavior, Animal / Q000187:drug effects; D001552:Benzazepines / Q000494:pharmacology; D004195:Disease Models, Animal; D015259:Dopamine Agents / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D007926:Lesch-Nyhan Syndrome / Q000139:chemically induced / Q000188:drug therapy* / Q000523:psychology; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D016627:Oxidopamine / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018967:Risperidone / Q000627:therapeutic use*; D012652:Self Mutilation / Q000188:drug therapy / Q000523:psychology; D013565:Sympatholytics / Q000633:toxicity*
D001552:Benzazepines; D015259:Dopamine Agents; D018492:Dopamine Antagonists; D013565:Sympatholytics; D007980:Levodopa; D016627:Oxidopamine; D018967:Risperidone